Cargando…

Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis?

We describe a case of a 48-year-old woman who presented with acute respiratory failure due to diffuse alveolar haemorrhage and acute renal failure due to pauci-immune glomerulonephritis consistent with a new diagnosis of microscopic polyangiitis (MPA). The patient had a recent SARS-CoV-2 infection 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Sukhraj, Vaghaiwalla, Zareen, Thway, Myint, Kaeley, Gurjit Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047981/
https://www.ncbi.nlm.nih.gov/pubmed/33846189
http://dx.doi.org/10.1136/bcr-2020-241125
_version_ 1783679153624580096
author Singh, Sukhraj
Vaghaiwalla, Zareen
Thway, Myint
Kaeley, Gurjit Singh
author_facet Singh, Sukhraj
Vaghaiwalla, Zareen
Thway, Myint
Kaeley, Gurjit Singh
author_sort Singh, Sukhraj
collection PubMed
description We describe a case of a 48-year-old woman who presented with acute respiratory failure due to diffuse alveolar haemorrhage and acute renal failure due to pauci-immune glomerulonephritis consistent with a new diagnosis of microscopic polyangiitis (MPA). The patient had a recent SARS-CoV-2 infection 6 weeks before MPA diagnosis and had stopped immunosuppression for her rheumatoid arthritis (RA) at that time. The patient was treated with pulse intravenous steroids, plasma exchange therapy and rituximab, which induced remission of her illness. This case highlights a timely dilemma of holding immunosuppression in a RA patient with low disease activity on combination therapy with SARS-CoV-2 infection, and the potential risk of developing an additional autoimmune disease, such as vasculitis, given their existing autoimmunity due to RA.
format Online
Article
Text
id pubmed-8047981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80479812021-04-28 Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis? Singh, Sukhraj Vaghaiwalla, Zareen Thway, Myint Kaeley, Gurjit Singh BMJ Case Rep Case Report We describe a case of a 48-year-old woman who presented with acute respiratory failure due to diffuse alveolar haemorrhage and acute renal failure due to pauci-immune glomerulonephritis consistent with a new diagnosis of microscopic polyangiitis (MPA). The patient had a recent SARS-CoV-2 infection 6 weeks before MPA diagnosis and had stopped immunosuppression for her rheumatoid arthritis (RA) at that time. The patient was treated with pulse intravenous steroids, plasma exchange therapy and rituximab, which induced remission of her illness. This case highlights a timely dilemma of holding immunosuppression in a RA patient with low disease activity on combination therapy with SARS-CoV-2 infection, and the potential risk of developing an additional autoimmune disease, such as vasculitis, given their existing autoimmunity due to RA. BMJ Publishing Group 2021-04-12 /pmc/articles/PMC8047981/ /pubmed/33846189 http://dx.doi.org/10.1136/bcr-2020-241125 Text en © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
spellingShingle Case Report
Singh, Sukhraj
Vaghaiwalla, Zareen
Thway, Myint
Kaeley, Gurjit Singh
Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis?
title Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis?
title_full Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis?
title_fullStr Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis?
title_full_unstemmed Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis?
title_short Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis?
title_sort does withdrawal of immunosuppression in rheumatoid arthritis after sars-cov-2 infection increase the risk of vasculitis?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047981/
https://www.ncbi.nlm.nih.gov/pubmed/33846189
http://dx.doi.org/10.1136/bcr-2020-241125
work_keys_str_mv AT singhsukhraj doeswithdrawalofimmunosuppressioninrheumatoidarthritisaftersarscov2infectionincreasetheriskofvasculitis
AT vaghaiwallazareen doeswithdrawalofimmunosuppressioninrheumatoidarthritisaftersarscov2infectionincreasetheriskofvasculitis
AT thwaymyint doeswithdrawalofimmunosuppressioninrheumatoidarthritisaftersarscov2infectionincreasetheriskofvasculitis
AT kaeleygurjitsingh doeswithdrawalofimmunosuppressioninrheumatoidarthritisaftersarscov2infectionincreasetheriskofvasculitis